Adenoviral vectors for treatment of hemophilia
US5935935A · kind A · utility
66Cited by
12References
65Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Aug 10, 1999 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S977/804
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.